Carrie Hersh, DO
Primary Location
Lou Ruvo Center for Brain Health - Las Vegas
- Appointment:
- 702.483.6000
- Fax:
- 702.483.6007
Specialty in Diseases & Conditions
- Acute Disseminated Encephalomyelitis (ADEM)
- Devic's Disease
- Multiple Sclerosis
- Optic Neuritis
- Transverse Myelitis
Insurance
Is Cleveland Clinic Nevada Part of Your Insurance?
For questions about accepted insurance plans for our Nevada locations and specific plan products including Medicare, please contact your insurance carrier directly.
View All PlansAbout Carrie Hersh, DO
Carrie M. Hersh, DO, MSc, FAAN joined the faculty at Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRCBH) in August 2015 as a specialist in multiple sclerosis (MS) and neuroimmunology and is Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CWRU). At CCLRCBH, she directs the MS Health and Wellness and Professional Engagement programs and is Associate Program Director of the MS and Neuroimmunology Fellowship. She completed a MS fellowship at the Cleveland Clinic Mellen Center through a National MS Society (NMSS) Sylvia Lawry Award. She earned a master’s degree in clinical research through the Clinical Research Scholars Program (CRSP) at CWRU. She completed her adult neurology residency training at Cleveland Clinic and graduated medical school with honors from Nova Southeastern University-College of Osteopathic Medicine. She earned her BS degree in microbiology and neurobiology at University of Florida, graduating summa cum laude, and is a member of Phi Beta Kappa. She is a Fellow of the American Academy of Neurology (AAN) and graduated from the AAN Women Leading in Neurology Program in 2023.
Dr. Hersh’s clinical research interests are in real-world evidence and comparative effectiveness studies. She is the principal investigator of clinical trials and investigator-initiated studies evaluating the effects of MS disease-modifying therapies on clinical, radiographic, and patient-reported outcomes. She also serves on international study steering committees. Dr. Hersh is a frequent lecturer on MS and neuroimmunology topics at national and international meetings, has a prolific publication record in peer-reviewed journals, and has been guest medical editor for MS publications.
Dr. Hersh has special interest in gender equity, professional engagement and development, and burnout prevention among healthcare professionals, for which she has directed national symposia and is published on this topic. She is also an Advanced Peer Coach through the Cleveland Clinic Center of Excellence in Coaching and Mentoring.
Dr. Hersh is Chair of national committees for the Multiple Sclerosis Association of America and Consortium of MS Centers (CMSC). She is also Secretary of the CMSC Board of Governors Executive Committee. Dr. Hersh is on the AAN Career Leadership Development Subcommittee and Wellness Subcommittee, serves on the NMSS National Medical Advisory Committee, and sits on national and international steering committees, expert panels, and advisory boards.
Education & Professional Highlights
Appointed
2015
Education & Fellowships
Graduate School - Case Western Reserve University School of Medicine
Clinical Research
Cleveland,
OH
2016
Fellowship - Cleveland Clinic
Neuroimmunology
Cleveland,
OH
2015
Residency - Cleveland Clinic
Neurology
Cleveland,
OH
2013
Internship - Cleveland Clinic
Internal Medicine
Cleveland,
OH
2010
Medical Education - Nova Southeastern University
Davie,
FL
2009
Undergraduate - University of Florida
Gainesville,
2005
Additional Training
Professional Highlights
- Peer Reviewed Publications:
- Hersh, CM. The effects of environmental challenges on nociception/orphanin FQ-induced anxiety. J Undergrad Res. 2005; 6(7). http://ufdc.ufl.edu/UF00091523/00330/1j.
- Hersh, C, Rae-Grant, A. Extended-release dalfampridine in the management of MS-related walking impairment. Ther Adv Neurol Disord. 2012; 5(4):199-204. doi: 10.1177/1756285612447091. PMID: 22783369.
- Hersh, CM, Cohen, JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014; 6(3): 249-259. doi: 10.2217/imt.14.7. PMID: 24762071.
- Hersh, CM, Hara-Cleaver, C, Rudick, RA, Cohen, JA, Bermel, RA, Ontaneda, D. Experience with fingolimod in clinical practice. Int J Neurosci. 2015; 125(9):678-85. doi: 10.3109/00207454.2014.969839. PMID: 25271798.
- Hersh, CM, Love, TE, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord. 2016 Nov; 10:44-52. doi: 10.1016/j.msard.2016.08.002. PMID: 27919497.
- Hersh, CM, John, S, Subei, A, Willis, MA, Kosmorsky, G, Prayson, RA, Bhimraj, A. Optic neuropathy and stroke secondary to invasive Aspergillus in an immunocompetent patient. J Neuroophthalmol. 2016 Dec; 36(4):404-407. doi: 10.1097/WNO.0000000000000361. PMID: 27031126.
- Hersh, CM, Love, TE, Bandyopadhyay, A, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017 Aug; 3(3):2055217317715485. doi: 10.1177/2055217317715485. PMID: 28890796.
- Moss, B, Rensel, MR, Hersh, CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017 Oct; 14(4):999-1017. doi: 10.1007/s13311-017-0563-6. PMID: 28785958.
- Vollmer, B, Ontaneda D, Bandyopadhyay, A, Cohn, S, Nair, K, Sillau, S, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in two centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580.
- Hua, LH, Hersh, CM, Morten, P, Kusel, J, Lin, F, Cave, J, Varga, S, Herrera, V, Ko, J. The impact of price reductions after loss of exclusivity in a cost-effective analysis: fingolimod versus intramuscularly-administered interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. J Manag Care Spec Pharm. 2019 Apr; 25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
- Vollmer, B, Ontaneda, D, Harris, H, Nair, K, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. doi:10.1016/j.jns.2019.116498. PMID: 31644992.
- Conway, DS, Hersh, CM, Harris, HC, Hua, LH. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Mult Scler J Exp Transl Clin. 2020 Jan 27; 6(1): 2055217320902488. doi: 10.1177/2055217320902488. PMID: 32064117.
- Hua, LH, Harris, H, Conway, D, Hersh, CM. Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. J Neurol. 2020 Aug;267(8):2214-2220. doi: 10.1007/s00415-020-09816-1. PMID: 32270292.
- Ontaneda, D, Tallantyre, EC, Raza, PC, Planchon, S, Nakamura, K, Miller, D, Hersh, C, Craner, M, Bale, C, Chaudhry, B, Gunzler, DD, Love, TE, Gerry, S, Coles, A, Cohen, JA, Evangelou, N. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. PMID: 32320842.
- Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups and Clinical Investigators: Hersh, C (I did not work closely with any of the listed authors on this publication). Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.N Engl J Med. 2020. PMID: 32757523.
- Mowry, E, Bermel, RA, Williams, JR, Benzinger, T, de Moor, C, Fisher, E, Hersh, CM, Hyland, MH, Izbudak, I, Jones, SE, Kieseier, BC, Kitzler HH, Krupp, L, Lui, YW, Montalban, X, Naismith, RT, Nicholas,, JA, Pellegrini, F, Rovira, A, Schulze, M, Tackenberg, B, Tintore, M, Tivarus, ME, Ziemssen, T, Rudick, RA. Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. PMID: 32849170.
- Hersh, CM, Harris, H, Ayers, M, Conway, D. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020 Oct 13;6(4):2055217320959815. doi: 10.1177/2055217320959815. PMID: 33110616.
- Hua, LH, Hersh, CM, Tian, F, Mowry, EM, Fitzgerald, KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2020 Nov 23;47:102637. doi: 10.1016/j.msard.2020.102637. PMID: 33276238.
- Hersh, CM, Harris, H, Conway, D, Hua, LH. Impact of switching from natalizumab to moderate versus high efficacy DMT in clinical practice. Neurol Clin Pract. 2020 Dec 10 (6) e53-e65; doi: 10.1212/CPJ.0000000000000809. PMID: 33510948. Received “Notable This Week” and “Most Read Article” designations.
- Morrison-Banks, E, Michtich, K, Hersh, CM. How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord. 2021 Mar 18;51:102913. doi: 10.1016/j.msard.2021.102913. PMID: 33839482.
- Hersh, CM, Brook, RA, Beren, IA, Rohrbacker, NJ, Lebson, L, Henke, C, Phillips, A. The implications of suboptimal treatment outcomes with disease-modifying drugs in employees with multiple sclerosis. J Med Econ. 2021 Mar 19;24:1:479-486.doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
- Hersh, CM, Kieseier, B, deMoor, C, Miller, D, Campagnolo, D, Williams, JR, Fitzgerald, K, Xiong, K, McGinley, M, Hyland, M, Ruddick, R, Ziemssen, T, Koulinska, I. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results of MS PATHS. 2021 Apr 15;7(2). doi: 10.1177/20552173211004634.
- Ziemssen, T, Giovannoni, G, Alvarez, E, Bhan, V, Hersh, C, Hoffman, O, Oreja-Guevara, C, Robles-Cedeno, R, Trojano, M, Vermersch, P, Dobay, P, Khwaja, M, Stadler, B, Rauser, B, Hach, T, Piani-Meier, D, Burton, J. MSProDiscussTM, a useful digital tool to evaluate early signs of multiple sclerosis disease progression in a real world setting. J Med Internet Res. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. PMID: 34612826.
- Cohen, JA, Bermel, RA, Grossman, CI, Hersh, CM, Hyland, H, Mowry, EM, Naismith, R, Naylor, ML, Nicholas, J, Rajbhandari, R, Singh, CM, Tintorè, M, Zabalza, A, Ziemssen, T, Williams, JR, Montalban, X, on behalf of the MS PATHS Investigators. IgG Immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS. Mult Scler. 2022 Jan 7;13524585211061343. doi: 10.1177/13524585211061343. PMID: 34994577.
- Hersh, CM, Altincatal, A, Kapadia, S, de Moor, C, Rudick, R, Williams, JR, Miller, C, Koulinska, I. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. PMID: 35024161.
- Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial: Hersh, CM. Lancet Neurol. 2022 Apr 25:S1474-4422(22)00143-0. doi: 10.1016/S1474-4422(22)00143-0. Epub ahead of print. PMID: 35483387.
- Conway DS, Briggs FB, Mowry EM, Fitzgerald KC, Hersh, CM. Racial disparities in hypertension management among multiple sclerosis patients. Mult Scler Relat Disord. 2022 Jun 15;64:103972. doi: 10.1016/j.msard.2022.103972. Epub ahead of print. PMID: 35728435.
- Amin, M and Hersh, CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2022 Oct 31. doi: 10.2217/nmt-2021-0058. Epub ahead of print. PMID: 36314777.
- Sotirchos, ES, Fitzgerald, KC, Singh, CM, Smith, MD, Reyes-Mantilla, M, Hersh, CM, Hyland, MH, Canissario, R, Simmons, S, Arrambide, G, Montalban, X, Comabella, M, Naismith, RT, Krupp, LB, Nicholas, JA, Ziemssen, T, Rudick, R, Fisher, E, Bermel, RA, Mowry, EM, Calabresi, PA. Associations of serum neurofilament light chain with clinical characteristics and radiological measures in a large real world MS population. Ann Clin Transl Neurol. 2022 Nov 25. doi: 10.1002/acn3.51704. Epub ahead of print. PMID: 36427295.
- Sullivan, AB, Hersh, CM, Rensel, R, Benzil, D. Leadership inequity, burnout and lower engagement of women in medicine. J Health Serv Psychol. 2023. https://doi.org/10.1007/s42843-023-00078-9.
- Hersh, CM, Morrow, SA, Williams, MJ, Amezcua, L, Halper, J, Wandersee, K. Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action. Int J MS Care. 2023 May 23. https://doi.org/10.7224/1537-2073.2023-039.
- Sotirchos, ES, Hu, C, Smith, MD, Lord, H, DuVal, A, Arrambide, G, Montalban, X, Akguen, K, Ziemssen, T, Naismith, RT, Hersh, CM, Hyland, MH, Krupp, LB, Nicholas, JA, Bermel, RA, Mowry, EM, Calabresi, PA, Fitzgerald, KC. Agreement between reference resources for blood neurofilament light chain levels in people with multiple sclerosis. Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957. doi: 10.1212/WNL.0000000000207957. Epub ahead of print. PMID: 37816633.
- Alvarez, E, Longbrake, EE, Rammohan, K, Stankiewicz, J, Hersh, CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Sep 15;79:105009. doi: 10.1016/j.msard.2023.105009. Epub ahead of print. PMID: 37783194.
- Hersh, CM. Contemporary topics in multiple sclerosis. Neurol Clin. 2024 Feb;42(1):xiii-xv. doi: 10.1016/j.ncl.2023.08.001. Epub 2023 Aug 26. PMID: 37980125.
- Aboseif, A, Roos, I, Krieger, S, Kalincik, T, Hersh, CM. Leveraging real world evidence and observational studies in treating multiple sclerosis. Neurol Clin. 2024 Feb;42(1):203-227. doi: 10.1016/j.ncl.2023.06.003. Epub 2023 Jul 21. PMID: 37980116.
- Hersh, CM, Morrow, SA, Williams, MJ, Amezcua, L, Halper, J, Wandersee, K. Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action. Int J MS Care. 2023 Sep-Oct;25(5):199-205. doi: 10.7224/1537-2073.2023-039. Epub 2023 Sep 14. PMID: 37720263; PMCID: PMC10503818.
- Alvarez, E, Longbrake, EE, Rammohan, K, Stankiewicz, J, Hersh, CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Nov;79:105009. doi: 10.1016/j.msard.2023.105009. Epub 2023 Sep 15. PMID: 37783194.
- Sotirchos, ES, Hu, C, Smith, MD, Lord, H, DuVal, A, Arrambide, G, Montalban, X, Akguen, K, Ziemssen, T, Naismith, RT, Hersh, CM, Hyland, MH, Krupp, LB, Nicholas, JA, Bermel, RA, Mowry, EM, Calabresi, PA, Fitzgerald, KC. Agreement between reference resources for blood neurofilament light chain levels in people with multiple sclerosis. Neurology. 2023 Dec 4;101(23):e2448-e2453. doi: 10.1212/WNL.0000000000207957. PMID: 37816633.
- Krieger, S, Cook, K, Hersh, CM. Understanding multiple sclerosis as a disease spectrum: Above and below the clinical threshold. Curr Opin Neurol. 2024 Jun 1;37(3):189-201. doi: 10.1097/WCO.0000000000001262. Epub 2024 Apr 9. PMID: 38535979; PMCID: PMC11064902.
- Hersh, CM, Pang, M, Miller, DM, McGinley, MP, Hyland, M, Ziemssen, T, Avila, RL. Comparison of time to clinically meaningful improvement in Neuro-QoL in patients treated with natalizumab vs ocrelizumab. Neurodegener Dis Manag. 2024;14(2):21-33. doi: 10.2217/nmt-2023-0047. Epub 2024 Apr 16. PMID: 38623894.
- Hersh, CM, Sun, Z, Conway, DS, Sotirchos, E, Fitzgerald, KC, Hua, LH, Ziemssen, T, Naismith, RT, Pellegrini, F, Grossman, C, Campbell, N. A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in Multiple Sclerosis Utilizing the MS PATHS Research Network. Mult Scler Relat Disord. 2024 Sep 2;91:105847. doi: 10.1016/j.msard.2024.105847. Epub ahead of print. PMID: 39260226.
- Hersh, CM, Gorritz, M, Chen, C, Tuly, R, Gu, Y, Gadkari, A, Brown, B, Shao, Q. Real-world persistence and adherence of ofatumumab versus oral and injectable disease modifying therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024 Nov;91:105888. doi: 10.1016/j.msard.2024.105888. Epub 2024 Sep 12. PMID: 39388747.
- Conway, DS, Toljan, K, Harris, K, Galioto, R, Briggs, FBS, Hersh, CM. Body Mass Index Trends Over Four Years in Persons with Multiple Sclerosis. Mult Scler Relat Disord. 2024 Dec 8;93:106218. doi: 10.1016/j.msard.2024.106218. Epub ahead of print. PMID: 39667128.
- Briggs, FB, Conway, DS, Hersh, CM, Fitzgerald, K, Mowry, E, Cohen, JA, Ontaneda, D. The onset of multiple sclerosis differs in Hispanic/Latinx Americans compared to non-Hispanic White Americans. Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976. Epub ahead of print. PMID: 39718152.
- Aboseif, A, Orme, D, Chitnis, T, Hersh, CM. Utilizing Heterogeneous Treatment Effects in Pursuit of Personalized Multiple Sclerosis Care. Practical Neurology. 01/2025.
- Amin, M, Harvey, T, Pineda, DM, Moss, B, Tai, M, Gadkari, A, Brown, B, Conway, DS, Hersh, CM. Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Accepted for publication: Neurodegener Dis Manag. 01/2025.
Certifications
- Psychiatry and Neurology - Neurology
Awards & Honors
- 2001 University of Florida Honors Program
- 2002 Phi Eta Sigma Honor Society, UF
- 2002 National Society of Collegiate Scholars
- 2002 Golden Key International Honor Society, UF
- 2004 National Dean’s List
- 2004 National Society of Collegiate Scholars Merit Award, UF
- 2004 Presidential Recognition, UF
- 2004 Chancellor’s List, UF
- 2004 University Scholars Program, UF
- 2004 Phi Kappa Phi Honor Society, UF
- 2004 Phi Beta Kappa, UF
- 2005-2009 Dean’s List, NSU
- 2006 Sigma Sigma Phi Honor Society, NSU
- 2009 Psi Sigma Alpha National Osteopathic Honor Society, NSU
- 2012 7th Annual MASTER MS Fellowship Program
- 2014 Consortium of MS Centers (CMSC) Scholarship Award
- 2015 American Academy of Neurology (AAN) Fellows Scholarship Award
- 2015 Neurological Institute Research Day Clinical Fellow Award, CCF
- 2016 Travel Grant Award, European Committee for Treatment and Research in MS (ECTRIMS) 2016
- 2016 Top Score Poster, ECTRIMS 2016
- 2016 Top Score Poster, ECTRIMS 2016
- 2016 Editor’s Choice for original research, Multiple Sclerosis and Related Disorders journal article “Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up”
- 2017 Travel Grant Award, ECTRIMS 2017
- 2018 Healthcare Headliner Award in Research/Science, Vegas Inc.
- 2018 Top Score Poster, ECTRIMS 2018
- 2019 Top Score Poster, ECTRIMS 2019
- 2020 Fellow of the American Academy of Neurology (FAAN)
- 2023 Graduate of AAN Women Leading in Neurology Program
- 2023 and 2024 Most Read and Cited Articles | Multiple Sclerosis and Related Disorders and Neurodegenerative Disease Management peer-reviewed journals
Innovations & Patents
Memberships
- Consortium of Multiple Sclerosis Centers
- National Multiple Sclerosis Society
- Multiple Sclerosis Association of America
- American Academy of Neurology
Research & Publications
See publications for Carrie Hersh, DO.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 12/5/2024, Dr. Hersh has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Consulting and/or Speaking. Dr. Hersh receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:
- HSC Acquisition, LLC
- MJH Healthcare Holdings, LLC
- Impact Education, LLC
- MedForce
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
145 Patient Satisfaction Reviews
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.
| Overall | Star Ratings | |
|---|---|---|
| Explains | 4.9 | |
| Courtesy, Respect & Concern | 4.9 | |
| Patient Rating of Doctor | 4.9 |
45 Patient Comments
© 2025 The Cleveland Clinic Foundation. All Rights Reserved. No part of this work may be altered, reproduced, stored in a retrieval system, or transmitted, in any form, by any means, whether electronic, mechanical, by photocopying, recording, or otherwise, without the prior written permission of the Cleveland Clinic.
Reviewed on Apr 15, 2025
Dr Hersh is excellent!
Reviewed on Apr 4, 2025
Dr Hersh was excellent!!! Her mannerisms were wonderful & she made you feel like you were her only patient. I wish more doctors would care like Carrie does
Reviewed on Apr 1, 2025
Dr. Hersh and everyone there are absolutely amazing!!
Reviewed on Apr 1, 2025
Dr. Hersh is the best!
Reviewed on Mar 26, 2025
Dr Hersh is always concerned with ones well being and does everything she can to help - she's awesome!
Reviewed on Feb 21, 2025
I had an amazing experience at the Cleveland clinic as Dr Hersh really took the time to listen to my medical history and performed a thorough examination. Dr Hersh shared my MRI images and educated both my husband and I on Multiple Sclerosis. I appreciate Dr. Hershsharing her concerns of us wanting to family plan and explain how it would be better for us to wait for at least a year to get this condition under control before trying to start family planning. I appreciate her being straight forward with us. We want the best for us before bringing a life into the world and I thank her for being so supportive. I know I'm in good hands and I pray for everyone who is also facing these challenges.
Reviewed on Jan 31, 2025
My provider treated me as a whole person and made me feel that every thing would be okay.
Reviewed on Jan 29, 2025
I love Dr. Hersh. She explains everything so well. Very kind and thoughtful!
Reviewed on Jan 24, 2025
So lucky to have Dr Hersh as my Neurologist! She's caring, smart, and the most helpful Doctor one can have.
Reviewed on Jan 22, 2025
Excellent doctor
Reviewed on Jan 21, 2025
Your staff and Dr. Hersh are top notch and extremely through! Coming from the Midwest, it is refreshing to work with an organization that is organized works for the right reasons! Thank you! PS and the building is incredible
Reviewed on Jan 14, 2025
Dr Hersch has a great bedside manner she gives the time needed to talk about whatever bothers you, she's graceful and calming. Shows patient compassion.
Reviewed on Jan 10, 2025
The doctor spent plenty of time going over mri's and plan of action. I'm very please with my visit.
Reviewed on Dec 18, 2024
First time in my 35 years of life I was treated with such genuine human compassion in any kind of medical situation. Dr. Hersh listened and seemed to really care about helping me live a quality life.
Reviewed on Dec 17, 2024
Everyone is so amazing! I love Dr. Hersh and all the staff I dealt with
Reviewed on Dec 4, 2024
I feel I am in good hands with Dr. Hersh, she is wonderful.
Reviewed on Dec 3, 2024
Dr. Hersh was great and really takes her time to get to know you and your condition.
Reviewed on Nov 15, 2024
Love this Doctor she is so caring
Reviewed on Nov 15, 2024
Dr. Hersh is very knowledgable and explains Issues and options very well.
Reviewed on Oct 15, 2024
Dr Hirsch is a very good doctor. She is extremely good and explaining everything with detail, patient and Amazing care for her Patients.
Reviewed on Oct 9, 2024
Dr Hersh was very thorough and professional. She seemed interested in working on all my concerns.
Reviewed on Oct 8, 2024
Excellent experience, the doctor explained everything to me.
Reviewed on Oct 4, 2024
My doctor and Cleveland clinic are there to help me unlike my last doctor
Reviewed on Oct 1, 2024
Dr Hersh is amazing and genuinely cares. She takes the time to listen, answer all questions & genuinely wants to help to the best of her abilities.
Reviewed on Oct 1, 2024
Appointments are far into the future; Dr. Hersch is in great demand (for good reason).
Reviewed on Oct 1, 2024
Dr. Hersch shows sincere and meaningful concern. She is like family.
Reviewed on Sep 13, 2024
Love Dr. Hersh. She's Awesome. Very thorough, takes time to explain and review.
Reviewed on Sep 6, 2024
I trust my provider and feel that I receive great care
Reviewed on Sep 3, 2024
While she was unable to make a diagnosis I felt better being treated by her than the other MANY neurologists I've seen. I truly believe she will get to the root cause of my symptoms.
Reviewed on Aug 30, 2024
Dr. Hersh us wonderful. She is patient, listens, and does not rush the appointment. She explains thoroughly what is planning.
Reviewed on Aug 28, 2024
I found Dr. Hirsch to be caring, communicative, and extremely generous with her time. The appointment lasted 45 minutes, much longer than many of my recent in-person doctors' appointments.I am very satisfied with the appointment and Dr. Hirsch.
Reviewed on Aug 9, 2024
I have no complaints. Keep up the good work.Dr. Hersh is an excellent, knowledgeable physician.
Reviewed on Aug 9, 2024
My experience with Dr.Hersh was very good she is very friendly and professional .
Reviewed on Aug 6, 2024
My dr was so amazing! She was kind explained everything.. She is the 1st Dr that I felt actually cared
Reviewed on Aug 6, 2024
She is the 1st Dr to care I'm more than happy to be in her care
Reviewed on Jul 30, 2024
Dr. H. Was amazing and warm, felt cared for
Reviewed on Jul 26, 2024
You can tell Dr Hersh tries very hard display interpersonal skills, however she failed to address the situation where I was left in the waiting area for 3hr as well as provide an alternative option for having the tests I was due to have as I no longer trust Cleveland Clinic nor want them to perform this test.
Reviewed on Jul 26, 2024
Dr. Hersh is the most caring and knowledgeable doctor I've ever had. She's one of the best MS Specialists anywhere!
Reviewed on Jul 10, 2024
Dr Hersh is absolutely the best doctor I have ever had! Thank you!
Reviewed on Jul 5, 2024
Dr. Hersh Is the best. We really love her, she cares about her patients and take the time to make them kind of happy.
Reviewed on Jun 12, 2024
I had a great experience with my doctor
Reviewed on May 15, 2024
Dr Hersch was very thorough during my appt. I felt very comfortable with her.
Reviewed on May 10, 2024
Excellent doctor
Reviewed on May 1, 2024
Dr. Hersh is the most thorough, professional, yet warm and family like doctor I have ever seen.
Reviewed on Apr 23, 2024
Dr Hersh and the Cleveland Clinic staff are amazing and always make us feel like the most important people there.